TCL Archive ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial. September 8, 2006
TCL Archive NCI Chips In $2 Million For AACR Meeting; Advisors, Senior Staff Not Consulted. June 20, 2003